Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10296 in Locally Advanced or Metastatic NSCLC
NCT02981108Phase 2Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (8 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Overall Response Rate up to 15 months and 1 more. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02981108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981108.